
    
      The study is composed of the following parts:

      Part 1 is a double-blind, placebo-controlled single ascending dose (SAD) escalation study of
      up to 10 cohorts (N = approximately 80) in healthy volunteers Part 2 is a double-blind,
      placebo-controlled multiple ascending dose (MAD) escalation study in up to 6 cohorts in
      healthy volunteers with asymptomatic atopic diathesis with a 12-day treatment period (daily
      dosing) and 4-day follow-up period (N = approximately 48) Part 3 is a single cohort, single
      dose, open-label crossover food effect study (N = approximately 12) in healthy volunteers
      Part 4 is a double-blind, placebo-controlled multiple dose study in up to 2 cohorts of
      healthy volunteers with asymptomatic atopic diathesis with a 12-day treatment period (twice
      daily dosing) and 4-day follow-up period (N = approximately 16) Part 5 is a double-blind,
      single dose, crossover formulation effect study (N = approximately 12) in healthy volunteers
      Part 6 is a double-blind, placebo-controlled multiple dose study in subjects with atopic
      dermatitis with a 4-week treatment period (twice daily dosing of LOU064) and 3-week follow-up
      period in approximately 16 subjects
    
  